Lupin reported a strong Q1 FY27 with net sales up 32% YoY to ₹8,277 crore and net profit at ₹1,417 crore. While US revenue was robust, the company projects a sequential decline for the rest of the year. Investors are watching pipeline execution amidst margin normalization guidance.
Lupin Pharmaceuticals Q1 FY27 Results
Net Profit: ₹1,417 crore | Net Sales: ₹8,277 crore
Reader Takeaway: Strong Q1 performance driven by US and India, but expect margin normalization and sequential revenue dip in the US.
What just happened
Lupin announced its financial results for the first quarter of FY27. The company reported a net profit of ₹1,417 crore on net sales of ₹8,277 crore, marking a significant 32% year-over-year increase in net sales. EBITDA rose by 42% year-over-year to ₹2,450 crore, with an EBITDA margin of 29.6%.
Why this matters
The robust performance in Q1 provides a strong start to the fiscal year. However, the management's guidance for a sequential decline in US revenue and an expected full-year EBITDA margin of 25% (down from Q1's 29.6%) suggests potential headwinds ahead. This signals a need for careful monitoring of future performance and the company's strategy to navigate competitive pressures.
The backstory
Lupin has been focusing on expanding its presence in key markets like the US and India. The US business has been a significant revenue driver, supported by strategic product launches. The Indian market continues to show consistent growth, outperforming the broader industry.
What changes now
The company's US segment achieved revenues of $366 million in Q1 FY27, a 30% year-over-year increase. However, the outlook for the remainder of FY27 anticipates a sequential quarterly revenue drop to $250–280 million due to competition. The India business posted revenue growth of 13.9% YoY to ₹2,380 crore.
Risks to watch
Key risks include increased competition and pricing pressure in the US market, particularly for products like Tolvaptan and Mirabegron. The company's ability to successfully launch over 50 products in the US over the next three years, including complex generics and biosimilars, will be crucial for long-term growth.
Peer comparison
(No specific peer comparison data provided in the filing.)
Context metrics (time-bound)
- Q1 FY27 Net Sales: ₹8,277 crore (up 32% YoY)
- Q1 FY27 EBITDA: ₹2,450 crore (up 42% YoY)
- Q1 FY27 EBITDA Margin: 29.6%
- Q1 FY27 EPS: ₹31.0
- Full Year FY27 EBITDA Margin Guidance: ~25%
What to track next
Investors should monitor the execution of Lupin's complex product pipeline, especially new launches in the US. The company's ability to manage margins amidst competitive pressures and deliver on its long-term growth strategy will be key factors to watch.